Over the last month, Cleveland-Cliffs (NYSE:CLF) has experienced a decrease of approximately 25% in its share price, a ...

What was once seen as a speculative technology venture is now in the spotlight, as investors regard it as a crucial element ...

Halozyme Therapeutics HALO is scheduled to report third-quarter 2025 results on Nov. 3, after market close. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at ...